• UC San Diego Health, a top-ranked US academic medical center, commences clinical use of CT:VQ™
• 4th US academic medical center to adopt CT:VQ™ within 4 months of FDA clearance
• Validates 4DMedical's commercialization strategy of establishing reference sites at prestigious institutions

4DMedical Limited (ASX:4DX), a global leader in respiratory imaging technology, announces that UC San Diego Health (UCSD) has entered into a commercial arrangement for the clinical use of CT:VQ™. UCSD is one of the nation's leading academic health systems, consistently ranked in the top 10 in the U.S. for Pulmonology & Lung Surgery. Led by Dr. Jonathan Chung, Chief of the Division of Cardiothoracic Imaging, UCSD's cardiothoracic imaging program is internationally renowned for pioneering advanced imaging techniques and clinical innovation. The addition of CT:VQ™ to UCSD's imaging portfolio positions the institution at the forefront of functional lung imaging, providing a contrast-free, high-resolution alternative to traditional nuclear medicine VQ scans. UCSD joins Stanford University, University of Miami, and Cleveland Clinic as the fourth U.S. academic medical centre (AMC) to deploy CT:VQ™ for clinical use within just four months of FDA clearance in August 2025. These deployments demonstrate the compelling clinical value proposition of CT:VQ™ and validate 4DMedical's commercialization strategy of establishing reference sites at the nation's most prestigious institutions to drive broader market adoption.

The momentum continues to accelerate, and 4DMedical looks forward to sharing further progress with shareholders as the company advances through 2026.